I-Mab Biopharma tests the combination of lemzoparlimab (anti-CD47 IgG4 antibody) and felzartamab (anti-CD38 IgG1 antibody) for treating relapsed/refractory (R/R) MM patients (NCT04895410). This evidence concerns the gene CD38 and Miyoshi myopathy.